FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 640 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR How Does Ovarian Cancer Form? A New Study Points to MicroRNA July 30, 2020 Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... July 30, 2019 After Chemotherapy, Selma Blair Embraces Her Buzzed “Patchy Charcoal” Hair November 8, 2019 FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma June 22, 2020 Load more HOT NEWS Could A Form of Cell Death Enhance Cancer Immunotherapy? Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma Coming together for Zynlonta Food for Thought: A Fresh Perspective on Nutrition
